LRa05 on glycemic control and gut microbiota in patients with type 2 diabetes.

BACKGROUND

Type 2 diabetes mellitus (T2DM) is a metabolic disorder linked to high blood glucose and gut dysbiosis. Probiotics like LRa05 may improve glycemic control and gut microbiota.

AIM

To explore the impact of LRa05 with hypoglycemic medications on glycemic control and intestinal flora in T2DM patients with gut dysbiosis.

METHODS

Seventy-six participants were randomly assigned to receive either LRa05 (0.1 g 2 × 10 CFU) ( = 38) or a placebo ( = 38) for 12 weeks. Baseline characteristics were recorded, and changes in glycated hemoglobin, fasting blood glucose, and other biochemical indices were assessed using repeated measures one-way analysis of variance. Additionally, gut microbiota diversity was analyzed through species accumulation and alpha and beta diversity metrics.

RESULTS

The intervention group showed statistically significant improvements in lipid profiles, particularly in high-density lipoprotein cholesterol levels, which increased significantly over time ( < 0.001). Additionally, fasting blood glucose was significantly reduced in the LRa05 group compared with the placebo group ( < 0.001). No significant changes were observed in glycated hemoglobin, insulin sensitivity, or systemic inflammatory markers such as C-reactive protein. Furthermore, gut microbiota analysis revealed significant shifts in composition following the intervention, particularly an increase in and a decrease in , indicating beneficial effects on gut health.

CONCLUSION

This study demonstrated that the combination of LRa05 and hypoglycemic medications positively impacted glycemic control, specifically reflected in improved levels of high-density lipoprotein and fasting blood glucose. Additionally, significant alterations in gut microbiota composition were observed in patients with T2DM, indicating a potential synergistic effect between gut health and blood glucose regulation.